SCHEMBL3018741

SCHEMBL3018741

O=C(O)N1Cc2c[nH]cc2C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.37
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 2/20 0.31
DPP9 Q86TI2 1/20 0.31
DPP7 Q9UHL4 1/20 0.31
NPC1 O15118 1/20 0.31
TP53 P04637 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RYR2 Q92736 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
HSP90B1 P14625 1/20 0.31
TRAP1 Q12931 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643075 0.85 NOTUM (0.42) NOTUMGABRA1GABRG2GABRB3GABRA3
SCHEMBL7095794 0.78 NOTUM (0.35) NOTUMGABRA1GABRG2GABRB3GABRA3
SCHEMBL27829328 0.76 NOTUM (0.34) NOTUMGABRA1GABRG2GABRB3GABRA3
SCHEMBL29758685 0.75 NOTUM (0.64) NOTUMHDAC8DPP9DPP7NPC1
SCHEMBL2533362 0.75 NOTUM (0.64) NOTUMHDAC8DPP9DPP7NPC1
Hydrochloric Acid SCHEMBL27847913 0.75 NOTUM (0.33) NOTUMHDAC8DPP9DPP7RYR2
SCHEMBL9243016 0.73 NOTUM (0.35) NOTUMHDAC8NPC1TP53RAB9A
SCHEMBL27773244 0.73 NOTUM (0.35) NOTUMHDAC8NPC1TP53RAB9A
SCHEMBL19926225 0.71 MEN1 (0.37) NOTUMDPP9DPP7HSP90B1TRAP1
SCHEMBL21807338 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104684915-A New bicyclic derivatives HOFFMANN LA ROCHE 2015-06-03 CN claimed
CN-101001860-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-07-18 CN claimed
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 WO disclosed
EP-3852791-A1 ACTIVATING PYRUVATE KINASE R Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
EP-3853206-A1 TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
WO-2020061378-A1 TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed
WO-2020061255-A1 ACTIVATING PYRUVATE KINASE R FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed
CN-109311897-A PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS 福马治疗股份有限公司 2019-02-05 CN disclosed
CN-104684915-A New bicyclic derivatives HOFFMANN LA ROCHE 2015-06-03 CN disclosed
CN-104487435-A Benzodioxanes in combination with other actives for inhibiting leukotriene production BOEHRINGER INGELHEIM INT 2015-04-01 CN disclosed
CN-101868464-B Thienopyrimidiene derivatives as PI3k inhibitors HOFFMANN LA ROCHE 2013-11-13 CN disclosed
EP-1987036-A1 HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
US-20080103125-A1 Heterocylic antiviral compounds ROCHE PALO ALTO LLC 2008-05-01 US disclosed
WO-2008034731-A1 OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 WO disclosed
CN-101065385-A Rifamycin derivatives for treating microbial infections CUMBRE PHARMACEUTICALS INC (US) 2007-10-31 CN disclosed
WO-2007093520-A1 HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed
WO-2007093515-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN LA-ROCHE AG (CH) 2007-08-23 WO disclosed
US-20070191406-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-08-16 US disclosed
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease ROCHE PALO ALTO LLC 2007-08-16 US disclosed
CN-101001860-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-07-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease CCR5, CXCR1, CXCR3 NOTUM 4101/4885GABRA1 597/4885GABRG2 1004/4885
US-20080103125-A1 Heterocylic antiviral compounds CCR5, ACKR3, CXCR3 NOTUM 4249/4885GABRA1 1366/4885GABRG2 2351/4885
US-20070191406-A1 Heterocyclic antiviral compounds CCR5, CX3CR1, CXCR1 NOTUM 4227/4885GABRA1 1851/4885GABRG2 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.